Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
Links
(5) - ARTICLES
subject heading
Number of the records: 1
openseadragon
This site uses cookies to make them easier to browse. Learn more about
how we use cookies.